Sengenics Corporation Announces New Collaboration to Advance Cancer Treatment

Sengenics Corporation and Duke Health announced a collaboration to redefine metastatic colorectal cancer treatment. This venture aims to explore the immune system’s response to immunotherapy, leveraging Sengenics’s KREX® technology to discover autoantibody biomarkers related to drug efficacy, resistance, and toxicity.